Home › NDC Lookup › RxCUI directory › RxCUI 2598352

Abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension [Triumeq] — RxCUI 2598352

RxNorm drug concept · Semantic branded drug
RxCUI 2598352 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2598352
Official nameAbacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension [Triumeq]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asabacavir 60 MG / dolutegravir 5 MG / 3TC 30 MG Tablet for Oral Suspension [Triumeq]; Triumeq PD 60 MG / 5 MG / 30 MG Tablet for Oral Suspension; abacavir 60 MG (as abacavir sulfate 70.2 MG) / dolutegravir 5 MG (as dolutegravir sodium 5.26 MG) / lamivudine 30 MG Tablet for Oral Suspension [Triumeq]
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)51,277 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dolutegravir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Dolutegravir blocks a step HIV needs to survive inside your body. The virus uses an enzyme called integrase to insert its genetic code into your cells — once it does that, your cel...
  • What exactly does dolutegravir do — how does it fight HIV?
  • You can take dolutegravir with or without food — there's no strict requirement. That said, food does increase how much of the medicine your body absorbs, so taking it with a meal c...
  • Can I take it with food, or does it have to be on an empty stomach?
📖 Read our full Dolutegravir guide →

🕸️ Concept Web — How Abacavir 60 MG / dolutegravir 5 MG / lamivudine... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension [Triumeq] RxCUI 2598352

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Abacavir 190521
    • Dolutegravir 1433868
    • Lamivudine 68244
    • Abacavir / dolutegravir / lamivudine 1546887
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Triumeq 1546889
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Abacavir / dolutegravir / lamivudine Tablet for Oral Suspension 2598347
    • Abacavir / dolutegravir / lamivudine Oral Liquid Product 2598346
    • Abacavir / dolutegravir / lamivudine Oral Product 1546884
    • Abacavir / dolutegravir / lamivudine Tablet for Oral Suspension [Triumeq] 2598351
    • Triumeq Oral Liquid Product 2598350
    • Triumeq Oral Product 1546892
    • Tablet for Oral Suspension 1861409
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension SCD · 2598348
  • Abacavir 60 MG SCDC · 2598345
  • Dolutegravir 5 MG SCDC · 2374559
  • Lamivudine 30 MG SCDC · 757686
  • Abacavir / dolutegravir / lamivudine Tablet for Oral Suspension SCDF · 2598347
  • Abacavir / dolutegravir / lamivudine Oral Liquid Product SCDG · 2598346
  • Abacavir / dolutegravir / lamivudine Oral Product SCDG · 1546884

Brand-Name Concepts

  • Abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG [Triumeq] SBDC · 2598349
  • Abacavir / dolutegravir / lamivudine Tablet for Oral Suspension [Triumeq] SBDF · 2598351
  • Triumeq Oral Liquid Product SBDG · 2598350
  • Triumeq Oral Product SBDG · 1546892
  • Triumeq BN · 1546889

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2598352 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49702-0231-13 30 TABLET, FILM COATED in 1 BOTTLE (49702-231-13) Triumeq ViiV Healthcare Company 2014-08-22
49702-0258-37 1 KIT in 1 CARTON (49702-258-37) * 90 TABLET, FILM COATED... Triumeq PD ViiV Healthcare Company 2022-03-30
Observed labelers: ViiV Healthcare Company (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.